When was kadcyla approved?

When did Kadcyla (ado-trastuzumab emtansine) get FDA approval?

Kadcyla (ado-trastuzumab emtansine, also known by the brand name Kadcyla) was approved by the U.S. Food and Drug Administration (FDA) on February 27, 2013. [1]

Was it approved for the same use as today?

Kadcyla’s initial approval came with specific indications, and the label has been expanded/updated since first approval. If you need the exact original indication wording versus the current label, tell me which patient population or line of therapy you care about (for example, HER2-positive metastatic breast cancer after certain prior treatments).

Source

1